No abstract

Pharmacoeconomic study of different preparations of botulinum toxin type A used for the treatment of cerebral palsy in terms of health of the Russian Federation was conducted. The aim of this study was to determine the most appropriate therapy of cerebral palsy from the pharmacoeconomic point of view. We compared three regimens: botulinum toxin type A-Dysport ® in combination with standard therapy, botulinum toxin type A-Botox ® in combination with standard therapy and standard therapy without the use of botulinum toxin. It should be noted that centrally acting muscle relaxant (Baclofen) was used in standard therapy, but BTA in this treatment scheme is not used to eliminate unwanted relaxation of the muscles. As a result, it was found that the regimen Dysport ® +standard therapy has the lowest cost-effectiveness ratio (11 608 rubles) in comparison with drug therapy Botox ® +standard therapy (12 879 rubles) and standard therapy with a centrally acting muscle relaxant without BTA (25 222 rubles) by the end of 2 years of treatment. According to the budget impact analysis at the end of 2 years for 1 patient the scheme Dysport ® +standard therapy was the least expensive form of therapy (1 079 500 rubles) in comparison with therapy Botox®+standard therapy (1 159 085 rubles) and standard therapy with a centrally acting muscle relaxant without BTA (1 210 678 rubles).

is an equally efficacious alternative to urinary derived FSH, Menopur®. One differences between these products is their delivery devices; Gonal f® is provided as a multidose pen, Menopur® in vials or multidose preparation, and Bemfola® as a fixed dose pen. The aim of this study was to determine the impact of delivery device on drug wastage and associated cost. Methods: A retrospective analysis of Gonal-f® and Menopur® prescription and usage data from five UK infertility clinics was conducted to identify the level of wastage occurring from IVF cycles. Data collected included: number IVF cycles conducted in previous 12 months; daily dose; length of treatment; dose adjustment following ultrasound scan and FSH formulation(s) prescribed. The drug wastage for each patient was calculated and results compared to the potential Bemfola® wastage for these patients. The wastage cost was then determined using NHS list prices. Results: A total of 4724 IVF cycles were incorporated into the analysis. Of the 4078 Gonal-f® cycles, overall drug wastage was 650,775IU (5.7% of total dose prescribed) equating to 160IU per patient. For the 646 Menopur® cycles the wastage was 190,163IU (11.6% of total dose prescribed) equating to 294IU per patient. Had Bemfola® been used in these patients, the wastage would have been reduced to 104IU and 61IU per patient respectively. The use of Bemfola®, across all cycles, results in a drug wastage reduction of 376,800IUs and an associated cost saving of £100,011. Extrapolating this data to the annual number of UK IVF cycles results in a potential cost saving of £1,157,579. ConClusions: Using Bemfola® as an alternative to Gonal-f® or Menopur® can potentially reduce drug wastage and associated costs to both patients and the NHS.

No abstract

Budget impact analysis is one of the main methods of